Effects of oral N-acetylcysteine on walking capacity, leg reactive hyperemia, and inflammatory and angiogenic mediators in patients with intermittent claudication

• Published in: American journal of physiology. Heart and circulatory physiology Vol. 309; no. 5; pp. H897 - H905
• Main Authors: da Silva, Jr, Natan D, Roseguini, Bruno T, Chehuen, Marcel, Fernandes, Tiago, Mota, Glória F, Martin, Priscila K M, Han, Sang W, Forjaz, Cláudia L M, Wolosker, Nelson, de Oliveira, Edilamar M
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.09.2015
• Subjects: Acetylcysteine - administration & dosage; Acetylcysteine - therapeutic use; Administration, Oral; Aged; Antioxidants - administration & dosage; Antioxidants - therapeutic use; Cell adhesion & migration; Chemokine CCL2 - blood; Clinical trials; Drug use; Endothelins - blood; Humans; Hyperemia - blood; Hyperemia - drug therapy; Inflammation - blood; Inflammation - drug therapy; Inflammatory diseases; Intermittent Claudication - blood; Intermittent Claudication - drug therapy; Leg - blood supply; Male; MicroRNAs - blood; Middle Aged; Nitric Oxide Synthase Type III - blood; Oxidative stress; Phosphatidylinositol 3-Kinases - blood; RNA-protein interactions; Vascular Cell Adhesion Molecule-1 - blood; Vascular Endothelial Growth Factor A - blood; Walking; microRNAs; microRNA-126; blood flow; intermittent claudication; N-acetylcysteine
• ISSN: 0363-6135; 1522-1539
• DOI: 10.1152/ajpheart.00158.2015

Increased oxidative stress and inflammation contribute to impaired walking capacity and endothelial dysfunction in patients with intermittent claudication (IC). The goal of the study was to determine the effects of oral treatment with the antioxidant N-acetylcysteine (NAC) on walking capacity, leg postocclusive reactive hyperemia, circulating levels of inflammatory mediators, and whole blood expression of angiogenic mediators in patients with IC. Following a double-blinded randomized crossover design, 10 patients with IC received NAC (1,800 mg/day for 4 days plus 2,700 mg before the experimental session) and placebo (PLA) before undergoing a graded treadmill exercise test. Leg postocclusive reactive hyperemia was assessed before and after the test. Blood samples were taken before and after NAC or PLA ingestions and 5 and 30 min after the exercise test for the analysis of circulating inflammatory and angiogenic markers. Although NAC increased the plasma ratio of reduced to oxidized glutathione, there were no differences between experimental sessions for walking tolerance and postocclusive reactive hyperemia. Plasma concentrations of soluble vascular cell adhesion protein-1, monocyte chemotactic protein-1, and endothelin-1 increased similarly following maximal exercise after PLA and NAC (P < 0.001). Whole blood expression of pro-angiogenic microRNA-126 increased after maximal exercise in the PLA session, but treatment with NAC prevented this response. Similarly, exercise-induced changes in whole blood expression of VEGF, endothelial nitric oxide synthase and phosphatidylinositol 3-kinase R2 were blunted after NAC. In conclusion, oral NAC does not increase walking tolerance or leg blood flow in patients with IC. In addition, oral NAC prevents maximal exercise-induced increase in the expression of circulating microRNA-126 and other angiogenic mediators in patients with IC.